NCT05037409View on ClinicalTrials.gov

Investigation of Safety, Tolerability, Immunogenicity and Pharmacokinetics of Single-Dose of PF-06823859 in Japanese Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

September 28, 2021

Primary Completion Date

March 27, 2022

Study Completion Date

March 27, 2022

Conditions
Healthy
Interventions
DRUG

PF-06823859

low dose or high dose intravenous infusion

DRUG

Placebo

Intravenous infusion

Trial Locations (1)

160-0017

Medical Corporation Shinanokai Shinanozaka Clinic, Shinjuku-ku

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05037409 - Investigation of Safety, Tolerability, Immunogenicity and Pharmacokinetics of Single-Dose of PF-06823859 in Japanese Healthy Participants | Biotech Hunter | Biotech Hunter